Abbott Nabs Approvals for DRG Invisible Trial System
Nov 20, 2018 @ 10:34

Abbott Laboratories has nabbed approvals for a chronic pain treatment device that patients can try before getting an implanted version of the technology. The Dorsal Root Ganglion (DRG) Invisible Trial System now has CE mark and a nod from FDA. The Abbott Park, IL-based company said patients who find adequate pain relief with DRG therapy can then have the Proclaim DRG System implanted.

Sourced through from:

Leave a Reply